Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

This publication has 17 references indexed in Scilit:

• Effect of Lipid-Lowering Treatment on Natural History of Heterozygous Familial Hypercholesterolemia in Past Three Decades
  The American Journal of Cardiology, 2011
• Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
  The American Journal of Cardiology, 2010
• A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
  Proceedings of the National Academy of Sciences, 2009
• Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
  Nature Clinical Practice Cardiovascular Medicine, 2008
• Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
  Journal of Lipid Research, 2007
• Long-term effects of LDL apheresis in patients with severe hypercholesterolemia
  Journal of Clinical Apheresis, 2005
• Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin
  American Heart Journal, 2004
• Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
  Nature Genetics, 2003
• Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management
  Atherosclerosis, 1999
• Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.
  BMJ, 1991